Study identifier:NIS-CAT-CRE-2007/2
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Non-interventional study investigating how effective secondary prevention patients are treated to their LDL-C targets
Hyperlipidemias
-
No
-
All
1096
Observational
18 Years +
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Oct 2014 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
A cholesterol/lipid profile screening project of high risk patients with hyperlipidaemia (secondary prevention) who already receive cholesterol-lowering therapy. Lipid profile and rate of patients who are treated to target (which is <100mg/dl for patients with high risk and <70mg/dl for patients at very high risk) are screened (hospital-based specialists). The doctors therapy decisions after the screening and possible reasons for these decisions will be documented. Our aim is to evaluate dosing habits, to evaluate how many patients are treated to their LDL-C target and to underline the importance of treating patients to their cholesterol targets.
Location
Location
Rohrbach, Upper Austria, Austria
Arms | Assigned Interventions |
---|---|
Patients at very high risk | - |
Patients at high risk | - |
Patients at medium risk | - |
Patients at low risk | - |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.